A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation

Nature Communications

Volumn 7, Issue , 2016, Pages

  Stobart, Christopher C ^a,b,j   Rostad, Christina A ^a,b   Ke, Zunlong ^c   Dillard, Rebecca S ^a,b   Hampton, Cheri M ^a,b   Strauss, Joshua D ^a,b   Yi, Hong ^d   Hotard, Anne L ^a,b,k   Meng, Jia ^a,b,l   Pickles, Raymond J ^e   Sakamoto, Kaori ^f   Lee, Sujin ^a,b   Currier, Michael G ^a,b   Moin, Syed M ^g   Graham, Barney S ^g   Boukhvalova, Marina S ^h   Gilbert, Brian E ⁱ   Blanco, Jorge C G ^h   Piedra, Pedro A ⁱ   Wright, Elizabeth R ^a,b,d   Moore, Martin L ^a,b   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h Sigmovir Biosystems Inc   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j BUTLER UNIVERSITY   (United States)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^l Alios BioPharma Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; LIVE VACCINE; MOTAVIZUMAB; OE4 VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; FUSION PROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY;

ANTIGEN; BIOENGINEERING; CHILD HEALTH; GENE; GENETIC ANALYSIS; IMMUNE RESPONSE; IMMUNOASSAY; PROTEIN; RESPIRATORY DISEASE; RODENT; VACCINE; VIRAL DISEASE; VIRUS;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CODON; CONFORMATIONAL TRANSITION; COTTON RAT; DNA MODIFICATION; GENE MAPPING; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGENICITY; NONHUMAN; POINT MUTATION; RAT; THERMOSTABILITY; VIRAL GENETICS; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHLOROCEBUS AETHIOPS; DRUG STABILITY; GENETICS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; PROTEIN ENGINEERING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIGMODONTINAE; TEMPERATURE; TUMOR CELL LINE; VERO CELL LINE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SIGMODON;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DRUG STABILITY; HUMANS; MICE, INBRED BALB C; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; TEMPERATURE; VACCINES, ATTENUATED; VERO CELLS; VIRAL PROTEINS;

EID: 85007014976     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13916     Document Type: Article

References (56)

1. Kim, H. W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
2. Schickli, J. H., Dubovsky, F., & Tang, R. S. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 5, 582-591 (2009).
3. Connors, M., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10, 475-484 (1992).
4. Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S. M., & Prince, G. A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502 (1990).
5. Wright, P. F., et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25, 7372-7378 (2007).
6. Collins, P. L., & Melero, J. A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162, 80-99 (2011).
7. Karron, R. A., et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci. Transl. Med. 7, 312ra175 (2015).
8. Meng, J., Lee, S., Hotard, A. L., & Moore, M. L. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 5, e01704-e01714 (2014).
9. Rostad, C. A., et al. A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats. J. Virol. 90, 7508-7518 (2016).
10. McLellan, J. S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
11. Ngwuta, J. O., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).
12. Krarup, A., et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
13. Palomo, C., et al. Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses. J. Virol. 90, 5485-5498 (2016).
14. McLellan, J. S., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
15. McGinnes Cullen, L., Schmidt, M. R., Kenward, S. A., Woodland, R. T. & Morrison, T. G. Murine immune responses to virus-like particle-Associated pre-And postfusion forms of the respiratory syncytial virus F protein. J. Virol., 6835-6847 (2015).
16. Liang, B., et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate. J. Virol., 9499-9510 (2015).
17. Kiss, G., et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J. Virol. 88, 7602-7617 (2014).
18. Liljeroos, L., Krzyzaniak, M. A., Helenius, A., & Butcher, S. J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl Acad. Sci. USA 110, 11133-11138 (2013).
19. Corti, D., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439-443 (2013).
20. Hotard, A. L., et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J. Virol. 89, 512-522 (2015).
21. Moore, M. L., et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. 83, 4185-4194 (2009).
22. Gilman, M. S., et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog. 11, e1005035 (2015).
23. Yunus, A. S., et al. Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Virology 396, 226-237 (2010).
24. Ling, Z., Tran, K. C., & Teng, M. N. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J. Virol. 83, 3734-3742 (2009).
25. Spann, K. M., Tran, K. C., & Collins, P. L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 79, 5353-5362 (2005).
26. Bukreyev, A., Whitehead, S. S., Murphy, B. R., & Collins, P. L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71, 8973-8982 (1997).
27. Karron, R. A., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093-1104 (2005).
28. Whitehead, S. S., et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73, 3438-3442 (1999).
29. Karron, R. A., et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA 94, 13961-13966 (1997).
30. Meng, J., et al. The respiratory syncytial virus attachment glycoprotein contribution to infection depends on the specific fusion protein. J. Virol. 90, 245-253 (2015).
31. Techaarpornkul, S., Barretto, N., & Peeples, M. E. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J. Virol. 75, 6825-6834 (2001).
32. Teng, M. N., Whitehead, S. S., & Collins, P. L. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289, 283-296 (2001).
33. Anderson, L. J., Bingham, P., & Hierholzer, J. C. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. 62, 4232-4238 (1988).
34. Polack, F. P., et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl Acad. Sci. USA 102, 8996-9001 (2005).
35. Tripp, R. A., et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2, 732-738 (2001).
36. Bukreyev, A., et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82, 12191-12204 (2008).
37. Johnson, T. R., McLellan, J. S., & Graham, B. S. Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J. Virol. 86, 1339-1347 (2012).
38. Yi, H., et al. Native immunogold labeling of cell surface proteins and viral glycoproteins for cryo-electron microscopy and cryo-electron tomography applications. J. Histochem. Cytochem. 63, 780-792 (2015).
39. Mayhew, T. M. Mapping the distributions and quantifying the labelling intensities of cell compartments by immunoelectron microscopy: progress towards a coherent set of methods. J. Anat. 219, 647-660 (2011).
40. Wright, P. F., et al. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J. Virol. 79, 8651-8654 2005
41. Hotard, A. L., et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434, 129-136 (2012).
42. Widjojoatmodjo, M. N., et al. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol. J. 7, 114 (2010).
43. Swanson, K. A., et al. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. J. Virol. 88, 11802-11810 (2014).
44. Stokes, K. L., et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 85, 5782-5793 (2011).
45. Zhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., & Pickles, R. J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76, 5654-5666 (2002).
46. Zhao, H., et al. A novel pregnane-Type alkaloid from Pachysandra terminalis inhibits methicillin-resistant Staphylococcus aureus in vitro and in vivo. Phytother. Res. 29, 373-380 (2015).
47. Jin, H., Cheng, X., Zhou, H. Z., Li, S., & Seddiqui, A. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J. Virol. 74, 74-82 (2000).
48. Mastronarde, D. N. Dual-Axis tomography: an approach with alignment methods that preserve resolution. J. Struct. Biol. 120, 343-352 (1997).
49. Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36-51 (2005).
50. Kremer, J. R., Mastronarde, D. N., & McIntosh, J. R. Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. 116, 71-76 1996
51. Galaz-Montoya, J. G., Flanagan, J., Schmid, M. F., & Ludtke, S. J. Single particle tomography in EMAN2. J. Struct. Biol. 190, 279-290 (2015).
52. Nicastro, D., et al. The molecular architecture of axonemes revealed by cryoelectron tomography. Science 313, 944-948 (2006).
53. Frank, J., et al. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J. Struct. Biol. 116, 190-199 (1996).
54. Pettersen, E. F., et al. UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
55. McLellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788-7796 (2011).
56. Wang, H., et al. Controlled growth of few-layer hexagonal boron nitride on copper foils using ion beam sputtering deposition. Small 11, 1542-1547 (2015).